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This paper offers Medicaid assistance for early HIV/AIDS treatment as a case 
study in reform of the status quo administration of Federal and state health 
systems and undertakes to provide a compelling case for early care to low-
income individuals with health needs.  Since the outbreak of HIV/AIDS in the 
United States in the early 1980s, Medicaid (and Medicare) eligibility require-
ments restrict benefits to HIV-positive individuals who are completely inca-
pacitated while access is deferred for those struggling in the interim before 
severe disability.  De facto, HIV-positive Medicaid recipients – low-income 
sufferers and the majority of infected persons of color –experience shorter life 
expectancies and lower qualities of life than their privately-insured counter-
parts.  Interventions addressing HIV-related illness among poor populations 
may also address an underlying cause of their low earnings, removing a 
barrier to work and encouraging employment by improving physical and 
emotional capacities as well as future life prospects.  
1. Introduction
1.1. Overview
Since the outbreak of HIV/AIDS in the United States in the early 1980s, 
Congress has extended in-kind treatment benefits to HIV-positive persons 
under Medicaid and, more recently, Medicare AIDS Drug Assistance 
Programs (ADAPs). People who do become infected and who cannot afford 
care eventually receive antiretroviral (ARV) therapy funded by Federal and 
state public health insurance; however, Medicaid imposes an eligibility 
Expanding Medicaid Coverage for Early Treatment 
of HIV-Positive Persons and Implications for 
Poverty Reduction
Keywords: HIV/AIDS, Medicaid, early treatment of HIV, Ryan White CARE 
Act
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requirement mandating a demonstration of “severely disability” as a condition 
for receiving AIDS treatment.  Medicaid (and Medicare) eligibility require-
ments restrict benefits to HIV-positive individuals who are completely 
incapacitated while access is deferred for those struggling in the interim 
before severe disability.  De facto, HIV-positive Medicaid recipients – low-
income sufferers and the majority of infected persons of color –experience 
shorter life expectancies and lower qualities of life than their privately-insured 
counterparts.  
Unfortunately, the story of Medicaid coverage for HIV/AIDS among low-
income populations in the United States is representative of Medicaid cover-
age for many other “disabling conditions.”  That this paper undertakes to dem-
onstrate the substantial potential gains to expanding access to early treatment 
for HIV symptoms should not be read as a “singling out” of HIV/AIDS to the 
exclusion of those illnesses also under covered by public insurance programs.  
On the contrary, this evaluation offers Medicaid assistance for early 
HIV/AIDS treatment as a case study in reform of the status quo administration 
of Federal and state health systems and undertakes to provide a compelling 
case for early care to low-income individuals with health needs.
Interventions addressing HIV-related illness among poor populations may 
also address an underlying cause of their low earnings, removing a barrier to 
work and encouraging employment by improving physical and emotional 
capacities as well as future life prospects.  In particular, single mothers with-
out access to health care and children of HIV-positive parents may benefit 
most from early ARV therapy through increased earnings.  Recommendations 
include: (1) raising the clinical threshold for care to enroll HIV-positive 
individuals in the “interim” before severe disability in early drug therapy and 
(2) raising the eligibility threshold for earnings to include those earning at or 
below 250 percent of the Federal poverty line.  Strategies for prevention 
outreach to disadvantaged populations of color and a discussion of macro 
(Federal- and state-level) and micro (individual-level) fiscal projections will 
locate these recommendations in the context of contemporary shifts in HIV 
infection and careful considerations of cost-effectiveness.
1.2. Research Methods
An extensive literature review constitutes the substance upon which the analy-
sis contained within this paper is built.  Rigorous evaluations of the effective-
ness of early HIV treatment and its cost-effectiveness for policymakers were 
given particular attention.  Recommendations are situated, as far as possible, 
within the limitations of extant knowledge and relative to present policy.
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2.  Overview of Federal HIV/AIDS Legislation
2.1. Medicaid Eligibility 
Antiretroviral therapy for HIV is recommended for all patients whose CD4 
cell counts have dropped below 350 per mL, yet Medicaid-insured HIV-
positive persons must wait to develop incapacitating physical symptoms 
before receiving treatment, though they meet clinical criteria for drug 
therapy.( Shapiro, 1999; Levi & Kates, 2000; Kahn,Haile, Kates & Chang, 
2001) This population is not enrolled in treatment at critical stages in the 
progression of its viral load toward full-blown AIDS because eligibility for 
Federal- and state-funded care requires that symptoms be “severe enough” to 
jeopardize one’s capacity to work and to be self-sufficient (SSI for People 
Living with HIV/AIDS, 2009). To qualify for Medicaid or Supplemental 
Security Income, an HIV-infected person must be no longer able to earn at 
least $700 per month as a result of disease complications (Graydon, T. 
Randolph, 2000). Thus people in the early stages of HIV, for whom early treat-
ment clinically predicts the postponement of AIDS disability, “face the catch-
22 of having eligibility [deferred] until they become disabled” (Kahn,Haile, 
Kates & Chang, 2001).
For persons whose HIV status has developed into full-blown AIDS (the fatal, 
final manifestation of HIV infection), Medicaid is the catch-all for end-of-
the-line care.  Medicaid covers 50 percent of all people and 90 percent of all 
children in the United States living will AIDS.  The majority of HIV-infected 
people qualify for Medicaid several years after becoming infected because 
they are both poor and incapacitated; 70 percent of those eligible meet the 
criteria of being low-income and permanently disabled (Kaiser Family Foun-
dation, 2009). An estimated 200,000 to 240,000 persons with AIDS are 
covered by Medicaid (Fleishman, 2005).
Since the 1990s, overall Federal and state spending on Medicaid-covered 
HIV/AIDS treatments has grown steadily in proportion to rising numbers of 
positive diagnoses, from $3 billion to $4.1 billion in 2000 (Health Care 
Financing Administration, 2000), while Medicaid expenditures on antiretrovi-
ral drugs almost tripled between 1996 and 1999 alone – increasing from $68 
million to $160 million, representing the largest increase in ARV expenditures 
in the period since 1984 (Health Care Financing Administration, 2007). Total 
Federal spending on HIV/AIDS has grown enormously, and the FY2010 
budget includes $25.9 billion for HIV programs (Kaiser Family Foundation, 
2009). Funding for Medicaid-covered ARV therapy has grown incrementally 
with reported infection rates, yet there has emerged a substantial cause for 
concern.  What appears to show a decline in the rate of new infections may in 
reality describe a demographic shift in prevalence: previously, young, white 
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homosexual-practicing men comprised the highest proportion of infected 
individuals; now, black women and homosexual-practicing black males are at 
the center of the epidemic.  As is discussed further below, these populations 
are “disconnected” from treatment services and are less likely to receive ARV 
therapy than whites, possibly accounting for the halt in the rise of outlays for 
treatment.
 
Despite the enormous increase in funding for HIV/AIDS-related programs, 
the majority of these increases continue to be “discretionary” – i.e., allocated 
to prevention and education efforts both within the United States and globally 
(Alagiri, Summers & Kates, 2002). Changes in Medicaid regulations have 
made meeting the requirements for receiving antiretroviral drugs increasingly 
difficult: In 1996, new welfare restrictions implemented under the Personal 
Responsibility and Work Opportunity Act (PRWORA) also limited the access 
to Medicaid for certain groups at-risk of HIV infection: women transitioned 
from “welfare to work” under the new Temporary Assistance to Needy Fami-
lies (TANF) program lost the Medicaid coverage that was part of a pre-1996 
Aid to Dependent Families with Children (AFDC) assistance package; regula-
tions removing substance abuse as a disabling condition excluded injecting 
drug users from receiving HIV treatment by virtue of their addiction (Levi & 
Kates, 2000). Both of these populations find themselves at high risk, though 
recent rises in the infection rates of low-income women of color coupled with 
exclusion from access to Medicaid-funded early treatment and health-related 
attention that may identify HIV infection itself or drops in CD4 cell count 
could predict declines in life expectancy and health measures for low-income 
single mothers without health insurance.
2.2. Medicare Coverage of HIV/AIDS
The passage of Medicare Part D in 2006 brought substantial changes in cover-
age to the lives of many HIV-positive individuals previously covered by Med-
icaid.  One quarter of the HIV-infected Medicaid-eligible population – 50,000 
to 60,000 people – were transferred to Medicare Part D, ex-President Bush’s 
prescription drug plan (Piper Report, 2005). Demographics again account for 
part of this shift: low-income homosexual-practicing men who were infect in 
the early 1980’s have recently become “elderly” and eligible for Medicare 
drug coverage, though barriers to receiving drug assistance are differentially 
strict with respect to Medicaid coverage: harsher formulas determine need and 
increasingly complicated applications mediate access drug regimens (Piper 
Report, 2005). HIV-positive people under 65 may also qualify to receive 
Medicare benefits if (1) “they are deemed disabled due to a physical or mental 
impairment that prevents them from working for a year or more or that is 
expected to result in death” and (2) “they have earned enough work credits to 
receive SSDI [Social Security Disability Insurance] payments … [after] a 
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5-month waiting period after becoming disabled before receipt of SSDI 
benefits and then a 24-month waiting period before an SSDI beneficiary can 
receive Medicare coverage, resulting in a total of 29 months before receipt of 
health benefits through Medicare for SSDI recipients” ( Kaiser Family Foun-
dation, 2006).
At present, the Centers for Medicare and Medicaid Services estimate that 
Medicare costs for HIV/AIDS drug therapy exceeds Medicaid costs, through 
Medicaid remains the “gateway” to receiving coverage as those who qualify 
for Medicare drug assistance become eligible, first, by being identified as 
“severely disabled” by Medicaid criteria and, second, as “in need” of a 
specific drug regimen by Part D according to the standards described above 
for possessing an “impairment exceeding one year” and having waited the 
necessary 29 months (OMB, CMS Office of the Actuary, HHS Office of 
Budget, 2008). Equivalent disability restrictions apply for those who pass 
directly Medicare without being assessed for Medicaid eligibility.  
The percentage of HIV-positive people who are covered by Medicaid and 
Medicare has not changed much since 1990.  In 1990, 40 percent of HIV-
infected people were covered by Medicaid (Kozak, McCarthy & Moien, 
1993); by 1996, this figure had risen to 44 percent (Kaiser Family Foundation, 
2006).  In 2008, this number has not changed (Chang, 2009). Dual coverage 
under Medicaid and Medicare varies at the state level, yet the proportion of 
those covered under Medicaid consistently comprises the majority of cases for 
those enrolled in some form of public care (Kaiser Family Foundation, 2006). 
It is not the magnitude of the “safety net” that is at issue – Federal funding of 
Medicaid and Medicare amounted to $4.1 billion and $4.5 billion, respec-
tively, in 2008 (Kaiser Family Foundation, 2009) – but rather the form in 
which it is extended.  Postponement of eligibility until “severe disability,” 
coupled with the absence of regulatory compensations in coverage for rises in 
“new types” of HIV-infected populations among populations of color 
(discussed below), leave a worrisome delay in need-for-care and access to 
life-sustaining treatment. 
2.3. Ryan White CARE Act
The focus of HIV policy has shifted to prevention.  To complement the 
substantial treatment “safety net,” innovative outreach programs – funded by 
discretionary outlays - emerged in urban centers seriously affected by viral 
spread in the mid-1990s as aggressive prevention efforts.  The Ryan White 
CARE Act was passed in 1990 to create a flexible source of funding for the 
changing requirements for intervention and treatment among low-income, 
uninsured persons affected by HIV/AIDS.  The Ryan White Act “fills in the 
gaps” in treatment for disconnected HIV sufferers while providing financial 
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support to prevention and education campaigns targeted to at-risk populations 
(United States Department of Health and Human Services, Health Resources 
and Services Administration, 2009); funding or the Act has grown since 1990 
as focus has shifted away from a Medicaid-based support system.  State- and 
city-level AIDS Drug Assistance Programs (ADAPs) seek greater flexibility 
in provision of services to HIV-infected populations and HIV-affected 
geographic regions, most commonly high poverty urban centers like Detroit, 
Chicago, Los Angeles, and New York City.
Under Ryan White, the Federal government subsidizes states and private 
non-governmental organizations in efforts to reach those HIV/AIDS sufferers 
not enrolled in Medicaid and to promote awareness about the virus in affected 
communities.  It is difficult to estimate the number of persons “covered under” 
Ryan White because prevention efforts, for example, extend to those already 
infect and in treatment as well as those who may pick up a provider’s pam-
phlet.  However, states may “clientize” the Ryan White funds they receive to 
target services to HIV-positive individuals.  In 2007, the State of North Caro-
lina reviewed its services to Ryan White aid recipients and found that 7,891 
patients were provided direct assistance, most often in the form of medical 
care (“N.C. Epidemiologic”, 2008). Funding for Ryan White in FY2008 
amounted to $2.2 billion, which was divided among states and then subdi-
vided among programs dedicated not only to treatment but also to vaccine 
research, advertisements, education programs, and evaluations of current 
programs (HRSA, n.d.).
The Ryan White CARE Act does not invest in extending early treatment 
services to HIV sufferers but seeks to “connect” them to medical care centers 
once they have neared Medicaid eligibility.  The “steering function” of Ryan 
White programs means that initiatives more often explore the effects of 
cultural stigma on an individual’s life with HIV/AIDS (Millbourne, 2009a) 
instead of addressing the gap in infection and access to treatment, with 
ambiguous implications for the HIV epidemic. When Ryan White-funded 
ADAPs do occasionally attempt to provide early drug access to patients, 
assignment of treatment is often ad hoc and scaled to community need – i.e., 
only the most needy may receive care; those making decisions about treatment 
must allocate Medicaid and Ryan White dollars to cover everyone in need, and 
more often than not funds are “woefully inadequate” (Cordena, 2004; Levi & 
Kates, 2000). The laudable “stopgap” functions have been under increasing 
stress as the “demands on Ryan White funding have increased” to meet the 
needs of those who are uninsured, requiring treatment, but not yet severely 
incapacitated by AIDS (Graydon, 2000). 
In the end, funds are zero-sum: spending on ARV therapy for low-income 
HIV-positive individuals who will eventually end up on Medicaid may seem 
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like a poor investment compared to the possible gains to community preven-
tion efforts or the equally necessary attention to “steering” recently-eligible 
people into care.  However, the allocation of funds and energy to stigma and 
education effectually universalizes an encounter with “interim” disability for 
low-income uninsured HIV-positive people.
3.  Medicaid and Living with HIV/AIDS
3.1.  Medicaid Coverage for Disabling Conditions
The limitedness of Medicaid coverage for HIV/AIDS is not unique to the 
virus and its health effects; rather, “interim” illness and deferral of treatment 
until severe disability is symptomatic of most Medicaid services to low-
income persons suffering from ailments.  A 2008 study by Andrew B. Bind-
man, et al., finds that state requirements to demonstrate Medicaid eligibility 
itself caused 62 percent of Medicaid recipients to experience an interruption 
in care that predicts a higher risk of hospitalization for heart failure, diabetes, 
and chronic obstructive pulmonary disease (Bindman, Chattopadhyay, & 
Auerback, 2008). Persons living in poverty experience higher probability of 
hospitalization: those respondents receiving Temporary Assistance to Needy 
Families are found to be at a “hazard risk” more than two times the risk of the 
general population of Medicaid beneficiaries surveyed.  
The issue is not that Congress is not allocating enough to diseases affecting 
low-income individuals who may qualify for Medicaid but that eligibility 
requirements prevent individuals in need from accessing vital care.  While the 
“necessity” of care ultimately resolves itself as a clinical question, the health-
related disadvantages of living at, below, or near the poverty line for sick 
persons offers a compelling case for reassessing the way in which access to 
care is presently extended.  
Why HIV/AIDS?  The focus of this paper on HIV seropositivity, the gains to 
early treatment, and the cost-effectiveness of eligibility expansion (discussed 
below) does not deprioritize the needs of HIV-negative Medicaid recipients 
suffering from other diseases but seeks to offer a particularized evaluation in 
the vein of what should, ideally, form part of a broader program of public 
health insurance reforms.
3.2.  Limitations of Medicaid Coverage for HIV-Infected Persons
Medicaid remains the primary care program for low-income HIV-infected 
persons; indeed, because the majority HIV-positive people are low-income 
(see footnote 7), Medicaid is the primary provider for all persons living with 
AIDS in the United States (Kahn,Haile, Kates & Chang, 2001). Despite its 
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inclusiveness for those whose viral load has progressed to full-blown AIDS, 
an HIV Cost and Services Utilization Study, beginning in 1996, found that 
HIV-infected persons enrolled in Medicaid fared worse (compared to 
privately-insured persons) in a nationally representative sample on six 
measures determinate of general health and access to basic HIV/AIDS treat-
ment:
 (1) Fewer than two office or outpatient visits in 6 months
 (2) Emergency department visit without an associated   
       hospitalization in 6 months
 (3) Hospitalization in 6 months
 (4) Did not receive PI or NNRTI therapy by December 31, 
      1996 if  recommendations for treatment were met
 (5) Never received antiretroviral treatment
 (6) Did not receive prophylaxis in the last 6 months for pneumocystis  
      carinii, a type of pneumonia to which persons with AIDS are 
      susceptible, if CD4 count was less than 200 (Health care financing  
      administration, 1996 - 1998).
Measures (4) – (6) demonstrate the comparative inaccessibility of ARV treat-
ment to Medicaid beneficiaries.  Measures (1) – (3) indicate that HIV-infected 
persons on Medicaid are generally sicker than those on private insurance plans 
– they are more likely to visit a doctor, emergency room, or hospital for HIV-
related complications.  The disparity between public-funded and private-
funded HIV health care is a statistical function of eligibility criteria: fewer 
HIV-infected Medicaid beneficiaries were receiving treatment compared to 
HIV-infected non-beneficiaries because the progression of their disease did 
not yet qualify them for ARV regimens.  That Medicaid recipients are also, on 
average, more prone to hospitalization indicates that beneficiaries experience 
more negative health shocks by virtue of their exclusion from early treatment.  
Moreover, because all those identified as “HIV-infected Medicaid beneficia-
ries” by HCSUS include also those already receiving ARV drug regimens 
through Medicaid, these findings additionally indicate that Medicaid-funded 
AIDS care for eligible recipients is inferior to private care.  While qualitative 
disparity in public/private care exists for almost all disease treatments, the 
HCSUS’s finding demonstrating a lower probability of having ever received 
ARV therapy among AIDS sufferers is an is particularly troubling.  This data 
indicates that low-income people diagnosed with full-blown AIDS are having 
their treatment deferred or that (as Bindman’s more general finding indicate) 
eligibility requirements interrupt the process through which drug regimens are 
obtained.
Medicaid has become an option of last resort in two senses: (1) for those 
whose HIV symptoms have finally qualified for benefits, and (2) for those 
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unable to access private care that meets the clinical standards for appropriate 
quality.  Comparisons of the health of HIV-positive, privately-insured persons 
and that of publicly-insured HIV-positive persons reveals that the “sicker” one 
gets the more likely a person is to be covered by Medicaid than a private insur-
ance plan.  In a 2003 follow up study to the HCSUS survey Dana Goldman, et 
al., investigated
A rule emerges in these analyses: low-income people living with HIV must 
wait until their symptoms become “so severe that they are disabled” (Levi & 
Kates, 2007).  The qualification of disability is linked explicitly to earnings, 
and the level at which it is set ($700/month) makes it paradoxically impossible 
for poor HIV-infected persons to pay for their own care in the interim.  The de 
facto result is a system by which Medicaid coverage is withheld until an AIDS 
sufferer is no longer able to support herself/himself, with “self-sufficiency” 
being defined as earning an annual income of at least $8,400 ($700/month) – 
a standard $2,430 below the official poverty threshold for a single earner, or 
(e.g.) for single mothers, $6,170 (one child) and $9,910 (two children) below 
the poverty line (Federal Register, 2009). For HIV-infected persons living at, 
marginally above, or below the poverty line, there exists no real support for 
early treatment, though HCSUS demonstrates its potential for preventing 
unexpected hospitalizations (and their associated costs) and despite the illogi-
calness of waiting until an AIDS sufferer’s income drops far below the 
poverty line before addressing the cause of her/his low earnings.
However, the counterfactual to the current “interim” delay is not immediately 
clear.  The effectiveness of reformed interventions offering access to early 
care will largely depend on the efficacy of treatment itself; cost-effectiveness 
will also be variable to drug prices and number of new enrollees such a change 
would invite into care.  Understanding the particular needs of HIV-positive, 
low-income persons will be essential to the recommendations extended below 
and should be an integral part of all reform efforts directed towards diseases 
affecting Medicaid recipients or potential Medicaid-eligibles.
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“the impact of disease severity on insurance coverage, the 
investigators used HCSUS data to develop a model to adjust 
for factors (for example, race, sex, HIV exposure route, 
education, time since diagnosis, and lowest CD4 lymphocyte 
count) that might affect insurance outcomes. Their findings 
indicate that the probability of having private insurance falls 
gradually from about 0.37 with a CD4 count of 700 (the 
normal count for healthy people is usually 600-1200) to 0.23 
as lowest CD4 count approaches zero. On the other hand, the 
probability of having public insurance rises dramatically 
from 0.36 to 0.67” (2003).
The current health needs of the population of low-income, HIV-positive 
persons are directly related to the present gap in treatment.  A 2000 study by 
Katz et al. evaluated the needs of a nationally-representative sample of HIV-
infected persons, those receiving Medicaid or Medicare assistance, those on 
private insurance plans, and those whose care was covered under the Ryan 
White CARE Act.  Respondents were asked to self-identify with five unmet 
needs: (1) income assistance or health care benefits (benefits advocacy), (2) a 
place to live (housing), (3) home health care, (4) mental health or emotional 
counseling (emotional counseling), and (5) drug or alcohol treatment 
(substance abuse counseling).  Sixty-seven percent of respondents possessed 
at least one unmet need, and 34.6% lacked necessary income assistance or 
health care benefits (benefits advocacy need), with declining requirements for 
each need included in the list above.  Most startlingly, only 60.3% of the 
sample had contact with a case manager in the past 6 months, meaning that 
only this percentage of HIV-positive adults were connected with a medical 
professional who was monitoring their health (Katz et al., 2000). Some 
variability was found across states as is common to Medicaid coverage in 
general.  However, the nature of Ryan White funding, which is allocated based 
on perceived need, means that states with large, urban-based HIV epidemics 
receive more aid and show greater coordination among HIV-related interven-
tions while states with rural populations of HIV-positive people are often 
particularly deprived of any meaningful care system.
3.3. Disproportionate Disadvantage for HIV-Infected Persons of Color
Disconnection is a serious problem for African American communities.  
HIV/AIDS infection rates have reached epidemic proportions among African 
American men and women.  Urban populations of black men who have sex 
with men (MSM) have HIV prevalence rates between 24.2 and 37.8 percent 
(City of Chicago Department of Health, 2008); young black MSM aged 13-19 
have seen their incidence of infection double since 2004 within the urban 
areas (Nikhil, 2009) - a rate more than twice that of white MSM (Centers for 
Disease Control, 2005). Hank Millbourne, Director of the AIDS Partnership 
of Detroit, asserts that “behaviors are just not lining up with knowledge about 
the disease” (2009b), and young black men are getting infected and avoiding 
much-needed treatment out of fear of stigma and exorbitant costs.  Addition-
ally, women of color living in areas of low socioeconomic status also find 
themselves the victims of a colluding combination of infection risks: high 
incarceration rates that deplete the pool of available males, sex for survival, 
and fluid sexual networks are prevalent in conditions of poverty.  Black men 
and women nationwide are at “approximately ten times” greater risk for HIV 
infection than whites (Centres for Disease Control and Prevention,2007).  The 
racialized impact of HIV/AIDS, however, is not new.  HIV prevalence in 
urban black communities boomed in the early 1990s when crack use and sexu-
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ally transmitted infection rates remained absent from the Center for Disease 
Control’s (CDC) AIDS interventions, creating a breeding ground for sexual 
interactions with high risks of infection (Levenson, 2004).  Presently, 68 
percent of HIV-positive females nationwide are African Americans, the 
majority of whom live below the poverty line (Ibid, n.d.).
William Julius Wilson’s hypothesis predicting the exponential circulation of 
“poverty ills” in areas of concentrated disadvantage here appears to have a 
particularly pertinent application.  Research suggests linkages between neigh-
borhood factors – or “ecologic stressors” – and the rate at which HIV 
progresses into AIDS.  Aiello, et al., report that “concentrated disadvantage, 
unequal income distribution, residential segregation, and poor quality of 
[one’s] built environment” produce statistically significant, positively associ-
ated effects for the progression from HIV to AIDS through “stress-related 
hormonal changes” (2008).  In the City of Detroit, 84 percent of people 
infected between the ages of 13 and 24 are black (Medical News Today, 
2008). While no studies have yet attempted to measure prevalence specific to 
race within the City of Detroit itself (due to complications involving move-
ment to and from the suburbs and the large intermixing of the subrurban and 
urban gay male populations), Richard Lichtenstein, Ph.D., compared preva-
lence for one Eastside zipcode within the city (48213) to prevalence for the 
city as a whole and found that the HIV infection rate has over 10 percent 
higher (24.92 percent) than for the city population; this zipcode is almost 
entirely African American (Lichtenstein, 2007).
 
These findings attest to the influence of environmental factors in HIV-related 
health problems beyond those traditionally-conceived to originate from 
individual sexual behaviors, socioeconomic status, or genetic markers.  Addi-
tionally, HIV-positive African Americans and Latinos are overall more likely 
to rely on Medicaid than HIV-positive whites (Kaiser Family Foundation, 
2006; 2004): in 2003, 59 percent of African Americans with HIV/AIDS relied 
on Medicaid, compared with 32 percent of whites (Fleishman, 2002; Ruiz, 
2003). Even within Medicaid African American HIV-infected Medicaid 
beneficiaries suffer greater disconnection from services: those eligible for 
HIV care on average enter treatment 8 months later and spend 8% less time on 
PI or NNRTI therapy than their non-Hispanic white counterparts (, Stephen, 
Sambamoorthi, Moynihan, & McSpiritt, 2001). Low-income HIV-infected 
African Americans on average are at higher risks for HIV infection and 
receive lower quality treatment on Medicaid than Medicaid recipient, HIV-
positive whites.  Addressing these disparities will require focusing special 
efforts on identifying differential racial characteristics attending to commu-
nity composition, culture, and socioeconomic status that uniquely disadvan-
tage this population to infection and exclusion from quality care.
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4. Poverty, HIV/AIDS, and Medicaid
As noted above, Medicaid eligibility requirements extend benefits only to 
“severely disabled” HIV-infected individuals earning below the poverty line, 
leaving low-income HIV sufferers to fend for themselves or to seek support in 
the patchwork of programs (under)funded by Ryan White outlays.  
Those in the “interim period” before developing severe disability and those 
newly alienated from public care have entered a burgeoning class of HIV-
infected persons living without any connection to medical assistance: of the 
850,000 to 950,000 people living with HIV in the United States, between 42% 
and 59% are estimated to not be in care (Kaiser Family Foundation, 2004). 
Rising HIV prevalence in areas of concentrated poverty and in limitations to 
access for at-risk, low-income populations increasingly make HIV/AIDS a 
disease of poverty, and Medicaid eligibility criteria ensure that if individuals 
are not already poor, they will become poor before being able to enroll in 
treatment.
What this “waiting game” means for households supported by HIV-infected 
adults is troubling.  In 2000, Shuster et al. estimated that 28% of HIV/AIDS 
sufferers had one or more children living with them; of that group, 75% had 
previously registered CD4 cell counts between 0 and 199 per mL, far below 
clinically recommended levels, and 30% (included within that 75% group) 
had full-blown AIDS (Shuster et al., 2000). Of all respondents sampled, 
83.3% earned less than $25,000/year; 56.5% earned less than $10,000/year.  
The households – containing approximately 100,000 children (Shuster et al., 
2000) – of low-income HIV-infected parents are likely to experience income 
shocks and rising health care costs as primary earners go without access health 
insurance, and it is not until many of these caregivers become functionally 
incapacitated that Medicaid care will finally be extended.  Maine and Massa-
chusetts (AIDS Action Council, 2004) have approved extending early treat-
ment to HIV-infected mothers, but evaluations have yet to be conducted 
regarding the number of new enrollees and effectiveness of treatment.  More-
over, income eligibility requirements are set at the poverty line and may not 
provide for the largely unpredictable health needs of those adults earning just 
above.
5. Gains to Early Treatment
5.1. Life Expectancy and Costs per Life Year Gained
Life for HIV-infected, low-income adults in the “interim” is not a life free 
from health problems, nor is deferring ARV therapy lack implications for 
future treatment outcomes.  Early treatment for HIV infection can signifi-
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cantly forestall the advent of AIDS and address the symptoms of HIV infec-
tion as they arise.  Medical advances since the early 1980s have “transformed 
[HIV/AIDS] from a rapidly fatal infection diagnosed at a late stage of the 
disease to a chronic progressive illness that affords many years of productive 
life under complex treatment regimens” (Graydon, 2000).
Kahn et al. (2000) modeled the health effects of extending Medicaid to HIV-
infected persons for early access to antiretroviral therapy.  The study found 
that if implemented nationwide the plan (over 5 years) would enroll 38,000 
more HIV patients in Medicaid, reduce AIDS diagnoses by 13,000, prevent 
2,600 deaths, and 5,816 life years to the population of HIV-infected Medicaid 
beneficiaries.  Over a 10 year period, life year gains are projected to increase 
by a magnitude of five, and the decline in AIDS deaths is expected to more 
than double.  
Federal costs for each five year period at current eligibility levels are 
estimated by Kahn et al. to be $24.3 billion; expanding early treatment is 
estimated to cost an additional $739 million over five years: Medicaid costs 
would rise by $1.43 billion, but decreases in costs for other programs (state 
ADAPS and SSI) would offset are projected to offset this rise (Kahn et 
al.,2000). The cost for quality adjusted life year gained (after five years) 
would be $879.97.  Kahn et al. offer two options for Federal budget neutrality: 
(1) bargain for lower drug prices, and (2) transition early treatment recipients 
back onto employment-based insurance – by subsidizing the purchase of 
“community-rated health insurance (i.e., by paying premiums for COBRA 
[Consolidated Omnibus Budget Reconciliation Act] to continue 
employment-based health coverage or for state high-risk pools)” insurance 
administration could replace inefficient plans that would continue to regulate 
HIV-positive Medicaid recipients as “high-risk” despite health improvements 
(2000).
A study conducted by Bruce Schackman et al. (2001) used a state-level simu-
lation model to estimate life expectancy and quality of life year gains for early 
antiretroviral treatment for HIV-infected persons nearing the CD4 cell count 
level at which treatment is clinically recommended.  Average gains in life 
expectancy for initiating early treatment at an intermediate CD4 level of 500 
per mL was 2.08 years (1.98 years when adjusted for quality of life) .  Gains 
to initiated treatment at an early stage in disease progression have yet to be 
evaluated but could offer greater life expectancies and improved quality of life 
for those interim years before full-blown AIDS develops.
Schackman et al. estimate the Federal cost per quality-adjusted life year 
gained to be approximately $17,300, but over a 5 year period total increases in 
taxpayer cost would amount to $11,500 per patient because early treatment 
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would simply require an earlier payment of the cost that is deferred at current 
Medicaid eligibility levels (2001). The disparity in Kahn’s and Schackman’s 
measures is explained, first, by Kahn’s discounting of declines in costs to state 
ADAPs and SSI and, second, by Kahn’s assumption of rising Medicaid 
HIV/AIDS costs in the next five years without expansion of early treatment.
5.2. Quality of Life and Increased Economic Productivity
For HIV-infected persons earning at the margins of the poverty line, basic 
improvements in health can produce increases in number of hours worked, 
level of productivity, motivation, and future life prospects.  While average 
gains of 2 years of additional life must not be taken out of proportion, at the 
very least, early treatment will help HIV sufferers avoid costly and unpredict-
able hospitalizations and will offer an opportunity to take their health under 
control.  Goldman et al. (2001) find that providing access to early treatment 
may show the greatest cost-effectiveness through reducing the high costs of 
hospitalizations. Adding productive years to the lives of HIV-infected earners 
can also encourage savings and planning for inability to work.  For thousands 
of children, extending the working life of an HIV-infected parent could mean 
the difference between growing up in poverty and not.
The costs of early therapy could also be offset by the contributions to GDP of 
HIV-infected workers given several extra years of working life as well as the 
additional taxes these workers may pay.  However, real cost gains accrue to 
HIV sufferers themselves: the high out-of-pocket costs of hospitalization, 
doctor visits, and uninsured health treatment that are common occurrences in 
the “interim” before severe disability put stress on already low incomes, and 
early treatment and coverage for health shocks could offer HIV-positive earn-
ers reprieve from unpredictable expenditures or burdensome debt to medical 
providers.
5.3. Cost-Effectiveness
The Medicaid program functions by making matching Federal funds available 
to states meeting the Congressional standards for provisions of care.  Since 
1982, states have participated, though there is substantial variation in the 
generosity of benefits, eligibility requirements, and provider payments 
(Kaiser Family Foundation, 2004). Only one state, Maine, has extended early 
access to drug therapy, though this change has yet to be evaluated.  Yet it 
seems that Congressional regulation mandating early treatment would impose 
costs variable to states’ populations of HIV-infected persons. 
 
Kahn’s and Schackman’s conflicting estimates, rather than testifying to the 
indecipherability of early treatment costs, make a case for a more systematic 
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reform to Medicaid coverage for eligible HIV/AIDS sufferers.  Bargaining for 
lower ARV costs should be explored: In 2007, Simpson et al. estimated the 
daily cost of ARV regimens to be between $52.75 per day (clinically symp-
tomatic) and $65.55 per day (severely symptomatic) based on the 50th and 
75th percentile of Medicaid mean drug costs for patients in South Carolina 
(Goldman et al., 2001). Annually, ARV costs on average are projected to be 
between $19,253.75 per patient and $29.925.55 per patient.  Medicaid covers 
these costs currently, and so the question becomes regarding the cost of 
extending ARV therapy earlier to HIV-positive persons.  
In light of current spending, Kahn et al.’s consideration of falling “alternative” 
program costs post-early treatment expansion and the proposals to bargain for 
reduced drug prices and to transition stabilized HIV-positive workers onto 
employment-based insurance present a compelling case for expanding cover-
age.  Additional costs of $879.97 per additional quality adjusted life year 
gained appears a marginal expense given the potential for increased earnings 
and reduced hospitalization costs.  Though it is difficult to model, tax 
revenues collected from populations of HIV-positive low-income individuals 
who may not be working as much or at all without early treatment could 
partially offset or even exceed Federal investment in their drugs regimens.
Public health insurance systems in Canada and the United Kingdom do 
provide early access to treatment for HIV-positive persons, though the effec-
tiveness of this care is mediated by general characteristics of care provision in 
each nation.  For example, it is difficult to access coverage, in general, for 
“high cost treatment for chronic or life-threatening diseases and conditions for 
Canadians who are working but have limited or no private insurance,” and 
ARVs are no exception (Kaiser Family Foundation, 2004). Recommendations 
for Medicaid coverage reform must inevitably be considered in the United 
States context, and limitations in the ability of other developed nation, public 
insurance system governments suggests the need for a comprehensive 
approach to individual insurance coverage and approaches to the potentially 
high costs of ARV regimens for those who are in need of intensive treatment.
5.4. Prevention Gains, Containment of Epidemic
For areas of concentrated disadvantage and high HIV prevalence, early 
antiretroviral therapy could address the rising rates of infection among discon-
nected populations.  HIV-positive persons in high-poverty centers, substance 
abuse is often also a problem (Katz et al, 2000), and given the spread of HIV 
through networks of crack cocaine distribution and use in largely African 
American urban communities, comprehensive health care for HIV-positive 
persons including drug and alcohol counseling could remove the enabling 
conditions for risky sexual behavior or unsanitary needle use.  Recent 
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randomized clinical studies evaluate to the effectiveness of alcohol and drug 
treatment in reducing HIV risk behaviors: Chawarski et al. (2008) found 
statistically significant 26 percent reductions in HIV risk behaviors among 
heroin dependent individuals in Muar, Malaysia, while an ongoing study (to 
be completed in 2010) measures the HIV risk behaviors of methadone patients 
(heroin users) in Wuhar, China (Katz. Et al., 2000.).
Moreover, extending treatment to members of disadvantaged communities of 
color could combat perceptions of alienation among others who are HIV-
infected.  Seeing HIV-positive persons receiving treatment with perceptible 
gains in life quality and life expectancy may encourage others to seek care.  
The disproportionately low levels of HIV care enrolment among seropositive 
African Americans (whether due to significant barriers to access or to cultural 
issues) requires attention.  Beyond the possibilities of preventing new infec-
tions and promoting the attractiveness of car enrolment, early treatment could 
also connect “disconnected” communities of low-income African Americans 
to medical centers and HIV education outlets in a way that promotes greater 
awareness about HIV/AIDS, sexual safety device availability, and knowledge 
strategies for infection risk aversion.  If there is a cultural or informational 
divide contributing to the epidemic-scale rates of infection among young men 
and women of color in urban settings, linking HIV-positive community mem-
bers to sources of not only treatment but also prevention knowledge and tools 
could make them empowered advocates for prevention and accessible 
resources for HIV-positive individuals curious about treatment options.
6. Recommendations
Congress should mandate that HIV-positive persons unable to afford private 
care be provided with early antiretroviral therapy funded by Medicaid:
(a)  Individuals will be eligible if their CD4 cell counts are 600 per mL or 
lower and will have access to medical case worker evaluations to determine 
appropriateness of various treatment regimens and to monitor the health of 
patients.  Kitahata et al. (2009) find that withholding treatment for CD4 counts 
of 500 per mL and above increases a patient’s risk of death by 94 percent 
(Chawarski, Mazlanb & Schottenfeld, 2008); because 500 CD4 cells per mL 
is the standard for evaluating the clinical appropriateness of care (Haller, 
Chawarski and Wang, n.d.), beginning evaluations of need for ARV therapy 
before this level may offer health returns for those patients whose CD4 counts 
may fluctuate and compromise immune systems. 
 
(b)  Income baselines should be set at 250 percent of the Federal poverty 
threshold for the recipient’s household type to compensate for illness occur-
ring before full-blown AIDS that may compromise the earnings of even those 
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with incomes above the poverty line.  Two hundred and fifty percent of the 
Federal poverty line is the current standard for access to Medicaid care for 
persons with cancer living in the State of New York, and the New York 
Department of Health’s assertion that this standard allows individuals to “gain 
access to life saving treatment and services” (Kitahata & Mari, 2009) trans-
lates informatively as a model for Medicaid coverage for HIV-positive, Med-
icaid eligible persons.  To understand early treatment as a support for earnings 
in the “interim” before severe AIDS-related disability is to conceive of an 
HIV-positive earner as economically self-sustaining.  However, current eligi-
bility requirements tied to an earnings level below the Federal poverty line 
does not allow medical support to intervene in critical stages of disease 
progression.  If evaluations for care eligibility begin at 250 percent of the 
poverty line, severe income shocks and enforced interim-period poverty can 
be dealt with before they redound not only to the HIV-positive persons imme-
diate subsistence, but also his/her future earnings and the prospects for his/her 
family and children.  H.R. 3962, the Affordable Health Care for America Act 
bill recently approved by the U.S. House of Representatives, establishes a 
criteria for Medicaid coverage at 150 percent the Federal poverty line (Kahn 
et al.,2000however, the marginal costs of extending treatment for HIV/AIDS 
(and its attendant costs) at an earlier stage in disease progression simply trans-
fer the bulk of expenditures per patient to a period before severe disability.  
Per Kahn et al.’s discussion of transferring HIV-positive earners onto private, 
employer-based insurance plans, a higher threshold for HIV-positive, low-
income persons could oddly keep such “eligible’s” off of Medicaid by stabi-
lizing their health and helping them to afford private insurance.
(c)  To facilitate the inevitable transition into severe illness and incapacitation 
for low-income, HIV-infected persons, Congress should also fund assistance 
programs that help early treatment recipients to save and plan for the future.  
Caseworkers should also be assigned to monitor the income status of families 
supported by an HIV-positive Medicaid-recipient earner and to coordinate 
eligibility and access to other means-tested income transfers (unemployment 
insurance, social security/disability insurance) and in-kind benefits (food 
stamps, subsidized child care).  This service would meet the “benefits advo-
cacy” need identified by more than one-third of HIV-positive persons and 
address the lack of access to caseworker review reported of 39.7% of this 
population (MCTP, n.d.). Though lack of caseworker access is a problem for 
other sick Medicaid recipients, enforcing new standards for care that are tied 
to income level and clinical definitions of treatment need (CD4 counts) may 
streamline access and make contact with caseworkers more readily enforce-
able.
(d)  Congress should also fund investigative inquiries (1) into Medicaid-
funded HIV/AIDS care provider programs that demonstrate lower quality 
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services compared to private providers, and (2) into the gap in Medicaid enrol-
ment in high-poverty African American communities with a guarantee that 
recommendations would be reflected in Medicaid eligibility rules and care 
standards or elsewhere in prevention education and HIV outreach program 
funding.
These changes will require Congressional legislation modifying current eligi-
bility requirements, for Federal policy requires that expansions in eligibility 
be budget neutral without explicit increases in expenditures allocated to cover 
increased program costs (H.R. 3962, Section 1017). A provision should also 
be included to link the scope of Medicaid-funded HIV/AIDS coverage medi-
cal advancements in treatment; as new technologies offer improvements to 
life expectancy and life quality, low-income HIV-infected persons should not 
be denied the same treatment options available to their privately-insured 
counterparts.
7. Discussion of Political Feasibility
The political feasibility of extending Medicaid coverage to include early 
antiretroviral therapy for low-income HIV-infected persons may encounter 
resistance.  Medicaid recipients lack political capital as an interest group: 
receiving increases in care funding must overcome general antipathy to 
increased welfare spending.  HIV-positive populations in particular face 
stigma that draws on moral and religious justifications.  However, HIV aware-
ness has made significant headway since the 1980s, and Congress has proved 
receptive to considering early treatment (as evidenced by its approval of 
Maine’s early ARV initiative).
The greatest resistance may focus on the costs of early treatment, but his 
concern, too, may not be convincing given the current political climate.  H.R. 
4972 includes significant changes to Medicaid and Medicare law that may 
affect HIV coverage for low income people (Katz et al., 2000).  The inclusion 
of this provision reflects the receptiveness of Congressional representatives to 
Medicaid extension to at-risk HIV sufferers and an implicit awareness of the 
unlikelihood of states to take action themselves.  Still, an authorization is far 
from a requirement mandating eligibility reform, though the provision may 
allow for funding leeway in states that choose to follow Maine’s example.
 
Winning mandatory requirements for early treatment will require strong advo-
cacy for reform, though generating substantial political will may depend on 
demonstrating success in individual states.  With the possible arrival of more 
accessible access to publicly-funded health care in the United States under the 
Obama administration, local and state actors should pursue funds that may 
become available to provide early treatment to those suffering in the interim 
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period before they become eligible for Medicaid.
8. Conclusion
Given the cost-effective gains in life expectancy and quality of life for low-
income HIV-positive persons of early clinical interventions for HIV-infected 
individuals, changes in Medicaid eligibility may carry substantial implica-
tions for the poverty that persists in the “interim” period before severe AIDS-
related disability.  The partial incapacitation of HIV-positive earners jeopar-
dizes not only personal health but also the wellbeing of the households that are 
supported by their labor.  Extending additional, productive years of life to 
low-income, HIV-positive persons may be the difference between living in 
poverty and not, with attendant implications for quality of life, ability to save, 
and child development.  Undeniably, the status of Medicaid coverage for 
HIV/AIDS among low-income populations in the United States is representa-
tive of Medicaid coverage for many other “disabling conditions.”  Though this 
paper “singles out” HIV/AIDS to the exclusion of those other illnesses also 
under covered by public insurance programs, the case for early treatment for 
HIV/AIDS is a study in dynamic potential that lies in reforming the Medicaid 
system in a more comprehensive fashion. 
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